Company profile
Home IXICO
IXICO is a premier medical imaging services provider, working with pharma and biotech partners to improve the outcomes of CNS trials.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
AP01 | Transaction MzQzMjYyMTEyNGFkaXF6a2N4
Published 19 Aug 2024 12:20
TM01 | Transaction MzQzMjYyMDY4MWFkaXF6a2N4
Published 19 Aug 2024 12:16
Company registered at Companies House
IXICO was co-founded by Professor Rueckert in 2004. IXICO's innovative technologies help those involved in researching and treating serious diseases to make rapid decisions and improve patient outcomes. Its clinical focus is predominantly dementia, but IXICO also support clinical studies for other disease areas in the field of neuro-degeneration and beyond. IXICO works with many of the leading pharmaceutical companies providing clinical trial services and technology to evaluate imaging endpoints as part of their drug development pipelines. Its medical image management and analysis products are used by the global pharmaceutical industry to select patients for clinical trials and to assess the safety and efficacy of drugs in development.
University spin out company that provides imaging services for clinical trials to the Pharmaceutical industry and is now developing a healthcare capability www.ixico.com
Economic impacts IXICO had a significant impact on the pharmaceutical industry where medical imaging is rapidly becoming an important tool in clinical trials to assess the safety and efficacy of new drugs using imaging biomarkers. IXICO's imaging biomarkers provide several benefits to pharmaceutical companies: In concept trials of AD therapies the developed biomarkers allow pharmaceutical companies to power their studies with fewer subjects. The developed imaging biomarkers do provide evidence of efficacy with around 100 subjects per arm (an "arm" in a clinical trial refers to any of the treatment groups in a randomized trial. Most randomized trials have two "arms", e.g. untreated vs. treated groups) over 12 months rather than 400 or so per arm needed for cognitive testing. Based on a conservative cost estimate of $30k per subject enrolled, this provides a significant cost saving for the companies. Similarly, pharmaceutical companies use the developed imaging biomarkers to enrich their clinical trials. In the context of clinical trials, such enrichment allows the identification of a population of patients in whom a drug effect, if present, is more likely to be demonstrable. In AD trials that use the developed biomarkers, an increase in the conversion rate in a prodromal Alzheimer's trial from 40% to 60% saves 30% off the cost of a pair of pivotal trials that used progression free survival as an endpoint, and which might otherwise cost $800m - $1bn. Impacts on public policy and services The imaging biomarkers developed in the underpinning research have had a significant impact on informing the development of new guidelines for the use of Magnetic Resonance Imaging (MRI) and low hippocampal volume in regulatory clinical trials: It now seems likely that to modify the course of Alzheimer's Disease, it is necessary to start the treatment in the pre-dementia (or prodromal) phase. The identification of patients at this stage can only be done confidently with the help of biomarkers: imaging provides a non-invasive alternative to cerebrospinal fluid (CSF) biomarkers for this purpose. The critical importance of imaging biomarkers in AD trials has been recognised by the CAMD consortium by submitting to regulators an application to qualify low hippocampal volume as a biomarker. This submission - approved by EMA and currently under review by the FDA - incorporates key data obtained using the underpinning research described here: the availability of this technology, with the regulatory qualification, is having global impact on the design of future trials of AD medicines in the pre-dementia population. In particular, the EMA Committee for Medicinal Products for Human Use has issued a positive opinion on the use of MRI to measure hippocampal volume as a tool to enrich recruitment into regulated clinical trials in the pre-dementia stages of Alzheimer's disease, in which the EMA directly refers to IXICO's technology. This was the first imaging-based biomarker to be qualified by a regulatory agency. Impacts on healthcare The imaging biomarkers developed in the underpinning research have been so effective in clinical trials that IXICO has recently decided also to develop products for diagnostic use (Brain Health Centre). IXICO's product for diagnostics directly uses the methods described in reference of the underpinning research and has also been CE marked. It is currently undergoing trials involving 200 patients as part of new NHS brain health centres.
Successful testing of new drugs with promise of better diagnosis methods from new product supported by award from the TSB launched dementia diagnosis product
1 Dec 2023 to 30 Nov 2024
IXICO is a premier provider of neuroimaging solutions, helping biopharmaceutical companies enhance their drug development pipelines through translating data into clinically meaningful insights. Bringing together world-class therapeutic expertise, breakthrough analytics, and operational excellence, IXICO is the proven partner of choice for imaging biomarke...
1 Feb 2019 to 31 Mar 2023
"The London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare will improve NHS patient care and health outcomes, reduce healthcare costs and support the growth of companies, supporting the economy. It will do this by applying artificial intelligence technologies to medical imaging (for example MRI scans, CT scans PET scans and ul...
1 Aug 2015 to 31 Aug 2015
Awaiting Public Project Summary
1 Apr 2015 to 30 Jun 2017
Most of the 700,000 people in the UK with dementia have not received a formal diagnosis, so are denied access to benefitial treatments. The current NHS approach is slow (often more than 12 months) and often of low quality. This project will further develop a novel digital healthcare system, allowing dementia diagnoses to be made quickly, cost effectively,...
1 Apr 2015 to 31 Mar 2018
Recent expensive failures in drug development to treat Alzheimer’s disease, the most common dementia, mean new efforts are needed to support those suffering without the hope of a cure. Several academic and industrial research collaborations are commencing, including the MRC Dementia Platform (UK), IMI-EPOC (EU), and DIANE (US). These projects are focused ...
1 Jan 2014 to 31 Dec 2015
There are currently no drugs for Alzheimer’s Disease, AD, available that stop or cure the disease. Results from recent clinical trials, where the drug has been shown not to work, suggest that many of those enrolled in the trial did not have AD at the start. While patients with AD are expected to deteriorate over the course of a trial in terms of their mem...
1 Jun 2013 to 30 Sep 2014
Timely and accurate Dementia diagnosis is a huge unmet need globally. As the population ages, the health and social care costs will rapidly become unsustainable. China may become the world's largest market for dementia diagnosis: China is estimated to have 25% of the world's dementia cases but ~80% of the dementia population remain undiagnosed, and the on...
1 Mar 2013 to 29 Feb 2016
Most of the 700,000 people in the UK with dementia have not received a formal diagnosis, so are denied access to benefitial treatments. The current NHS approach is slow (often more than 12 months) and often of low quality. This project will develop a novel digital healthcare system that will allow dementia diagnoses to be made quickly, cost effectively, a...
1 Oct 2007 to 30 Sep 2010
Awaiting Public Summary
1 Nov 2005 to 28 Feb 2009
Awaiting Public Summary
